Qatar Airways announced it will further increase flight frequencies and the number of destinations in China if the industry environment and local policies permit.
The carrier said it is gradually resuming its flights globally and China's impressive COVID-19 control measures encouraged it to increase services between the two countries.
Nearly 80 percent of Qatar Airways flights have resumed, faster than many other large-scale carriers, despite the global air travel market still reeling from the COVID-19 impact.
Qatar Airways resumed passenger service from Hangzhou, Zhejiang province to Doha using a Boeing 777-300ER aircraft, making it the sole e carrier servicing the route.
The return flight from Doha to Hangzhou will only carry cargo. In July, the carrier resumed weekly flights between Doha and Guangzhou, Guangdong province.
The flights from Hangzhou will join services from Guangzhou to Doha, and flights from Hong Kong with connections through Qatar Airways' partners for passengers from Beijing and Shanghai.


Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows
Standard Chartered Expands Hedge Fund Access for Wealth Clients
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut
Shein Targets $26B-$27B Valuation for Hong Kong IPO
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion
Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push
Lockheed Martin Secures $153.5 Million in U.S. Defense Contracts
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 



